Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

venetoclax 6Azacitidine 6Cytarabine 5fludarabine 4Methotrexate 3fludarabine phosphate 2aldesleukin 2RO6839921 2Mitoxantrone 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Decitabine 2Dasatinib 2zileuton 1thymoglobulin 1spartalizumab 1sabatolimab 1quizartinib 1pulrodemstat besilate 1posaconazole 1plerixafor 1gilteritinib 1etoposide phosphate 1emvododstat 1daratumumab 1blinatumomab 1Sorafenib 1Sirolimus 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid × zileuton × Clear all
NCT02047149 2016-09-30

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡